Cyclooxygenase-2 induction in macrophages is modulated by docosahexaenoic acid via interactions with free fatty acid receptor 4 (FFA4)

FASEB J. 2013 Dec;27(12):4987-97. doi: 10.1096/fj.13-235333. Epub 2013 Sep 4.

Abstract

Cyclooxygenase-2 (COX-2)-derived prostaglandins are implicated in numerous inflammatory disorders. The purpose of these studies was to examine previously unexplored interactions between COX-2 induction and docosahexaenoic acid (DHA) via the free fatty acid receptor 4 (FFA4) signaling pathway in murine RAW 264.7 cells and peritoneal macrophages challenged with lipopolysaccharide (LPS). DHA dose (IC50=18 μM)- and time-dependently reduced COX-2 expression, without affecting COX-1. DHA (25 μM for 24 h) decreased LPS-induced prostaglandin E2 (PGE2) synthesis by 81%, primarily through reducing COX-2 (60%), as well as down-regulating microsomal prostaglandin E synthase-1 (46%), but independently of peroxisome proliferator-activated receptors. FFA4 knockdown abrogated DHA effects on COX-2 induction, PGE2 production, and interleukin 6 (IL-6) gene expression. In the presence of inhibitors of eicosanoid metabolism via COX-2, 12/15-lipoxygenase and CYP450s (rofecoxib (1 μM), PD146176 (2 μM), or MS-PPOH (20 μM)), DHA was still effective in attenuating COX-2 induction. Moreover, Toll-like receptor 4 signaling via Akt/JNK phosphorylation and p65 nuclear translocation was repressed by DHA-activated FFA4 coupling with β-arrestin 2, which was reversed by FFA4 knockdown. These data support DHA modulation of COX-2 expression and activity, in part, via FFA4, which provides a new mechanistic explanation for some of the anti-inflammatory effects of DHA.

Keywords: GPR120; inflammation; prostaglandin; ω3 polyunsaturated fatty acids.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arrestins / metabolism
  • Cell Line
  • Cyclooxygenase 2 / genetics
  • Cyclooxygenase 2 / metabolism*
  • Cytochrome P-450 Enzyme Inhibitors
  • Dinoprostone / biosynthesis
  • Docosahexaenoic Acids / pharmacology*
  • Interleukin-6 / genetics
  • Interleukin-6 / metabolism
  • Intramolecular Oxidoreductases / metabolism
  • Lactones / pharmacology
  • Lipopolysaccharides / pharmacology
  • Lipoxygenase Inhibitors / pharmacology
  • MAP Kinase Kinase 4 / metabolism
  • Macrophages / drug effects
  • Macrophages / metabolism*
  • Mice
  • Mice, Inbred C57BL
  • Peroxisome Proliferator-Activated Receptors / metabolism
  • Prostaglandin-E Synthases
  • Proto-Oncogene Proteins c-akt / metabolism
  • Receptors, G-Protein-Coupled / genetics
  • Receptors, G-Protein-Coupled / metabolism*
  • Sulfones / pharmacology
  • Toll-Like Receptor 4 / metabolism
  • beta-Arrestin 2
  • beta-Arrestins
  • eIF-2 Kinase / metabolism

Substances

  • Arrb2 protein, mouse
  • Arrestins
  • Cytochrome P-450 Enzyme Inhibitors
  • FFAR4 protein, mouse
  • Interleukin-6
  • Lactones
  • Lipopolysaccharides
  • Lipoxygenase Inhibitors
  • Peroxisome Proliferator-Activated Receptors
  • Receptors, G-Protein-Coupled
  • Sulfones
  • Tlr4 protein, mouse
  • Toll-Like Receptor 4
  • beta-Arrestin 2
  • beta-Arrestins
  • interleukin-6, mouse
  • rofecoxib
  • Docosahexaenoic Acids
  • Ptgs2 protein, mouse
  • Cyclooxygenase 2
  • Proto-Oncogene Proteins c-akt
  • eIF-2 Kinase
  • MAP Kinase Kinase 4
  • Intramolecular Oxidoreductases
  • Prostaglandin-E Synthases
  • Dinoprostone